Human immunodeficiency virus type 1 drug susceptibility during zidovudine (AZT) monotherapy compared with AZT plus 2',3'-dideoxyinosine or AZT plus 2',3'-dideoxycytidine combination therapy. The protocol 34,225-02 Collaborative Group (Q39876026)
scientific article published on September 1996
Language:
(P31) (Q13442814)
(P50) (Q64746883)
(P304) 5922-5929
(P407) (Q1860)
(P433) 9
(P478) 70
(P577) Sunday, September 1, 1996
(P921) (Q1145523)
(Q198504)
(P1433) (Q1251128)
(P1476) "Human immunodeficiency virus type 1 drug susceptibility during zidovudine (AZT) monotherapy compared with AZT plus 2',3'-dideoxyinosine or AZT plus 2',3'-dideoxycytidine combination therapy. The protocol 34,225-02 Collaborative Group" (language: en)
(P2093) Larder BA
Kohli A
Bloor S
Kemp SD
Harrigan PR
Lange JM
Pennington KN
St Clair MH
(P2860) (Q24684152)
(Q28378727)
(Q28378547)
(Q40284727)
(Q34337590)
(Q40596576)
(Q40563206)
(Q28368052)
(Q34594711)
(Q39868599)
(Q28367547)
(Q28367543)
(Q28367526)
(Q37152061)
(Q28340342)
(Q28339571)
(Q28324214)
(Q28324076)
(Q28316118)
(Q28343184)
(Q28342653)
(Q40953652)
(Q45783355)
(Q42278116)
(Q41698277)
(Q45873929)
(Q44381031)
(Q45789356)
(Q45790013)
(Q72547970)
(Q71120796)
(Q57832598)
(Q59096959)
other details
description scientific article published on September 1996

External Links